Adding liraglutide to oral antidiabetic drug therapy: Onset of treatment effects over time

International Journal of Clinical Practice

Volumn 64, Issue 2, 2010, Pages 267-276

  Gallwitz, B ^a   Vaag, A ^b   Falahati, A ^c   Madsbad, S ^d  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b STENO DIABETES CENTER   (Denmark)

^c NOVO NORDISK A S   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG SAFETY; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FASTING; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; NAUSEA; YOUNG ADULT;

EID: 72449154207     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02265.x     Document Type: Article

References (32)

1. Stratton IM, Adler AI, Neil HAW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 321 : 405 412.
2. Virally M, Blicklé JF, Girard J et al. Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives. Diabetes Metab 2007 33 : 231 244.
3. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 32 : 193 203.
4. Turner RC, Cull RA, Frighi V et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999 281 : 2005 2012.
5. McFarlane SI, Jacober SJ, Winer N et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centres. Diabetes Care 2006 25 : 718 723.
6. Fox KM, Gerber RA, Bolinder B et al. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom General Practice Research Database: a series of retrospective analyses of data from 1993 through 2002. Clin Ther 2006 28 : 388 395.
7. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. J Nat Rev Endocrinol 2009 5 : 262 269.
8. Gilbert MP, Pratley RE. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. Am J Med 2009 122 (Suppl. 6 S11 24.
9. Nauck MA, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes. Diabetes Care 2009 32 : 84 90.
10. Marre M, Shaw J, Brandle M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic control and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009 26 : 268 278.
11. Zinman B, Gerich J, Buse J et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009 32 : 1224 1230.
12. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997 277 : 925 926.
13. Garber A, Henry R, Ratner R et al. Monotherapy with liraglutide, a once-daily human GLP-1 analog, provides sustained reductions in A1C, FPG, and weight compared with glimepiride in type 2 diabetes: LEAD-3 mono 2-year results. Diabetes 2009 58 (Suppl. 1 162-OR.
14. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 359 : 1577 1589.
15. Chang AM, Jakobsen G, Sturis J et al. The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003 52 : 1786 1791.
16. Cryer PE, Childs BP. Negotiating the barrier of hypoglycaemia in diabetes. Diabetes Spectr 2002 15 : 20 7.
17. Whitmer RA, Karter AJ, Yaffe K et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009 301 : 1565 1572.
18. Bruce DG, Davis WA, Casey GP et al. Severe hypoglycaemia and cognitive impairment in older patients with diabetes: the Fremantle diabetes study. Diabetologia 2009 52 : 1808 1815.
19. Frid A, Hermansen K, Nauck M et al. Long-term sustained glycaemic control with liraglutide and glimepiride (both plus metformin), with added benefits of weight loss and less hypoglycaemia with liraglutide: 2-year LEAD-2 data. Diabetologia 2009 52 (Suppl. 1 OP01.
20. Look AHEAD Research group. Reductions in weight and cardiovascular disease risk factors in individuals with type 2 diabetes. Diabetes Care 2007 30 : 1374 1383.
21. Klein S, Sheard NF, Pi-Sunyer X et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies. A statement of the American diabetes association, the North American association for the study of obesity, and the American society for clinical nutrition. Diabetes Care 2004 27 : 2067 2073. (Pubitemid 38989258)
22. American Diabetes Association. Standards of medical care - 2008. Diabetes Care 2008 31 (Suppl. 1 S12 54.
23. Turner RC, Millns H, Neil HAW et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998 316 : 823 828.
24. Adler AI, Stratton IM, Neil HAW et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000 321 : 412 419.
25. Patel A, ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007 370 : 829 840.
26. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998 317 : 703 713.
27. Holman RR, Paul SK, Bethel MA et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008 359 : 1565 1576.
28. Rosenstock J, Rood J, Cobitz A et al. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab 2006 8 : 650 660.
29. Slama G, Eschwè E, Bernard MH et al. One-year follow-up in real clinical practice conditions of type 2 diabetic patients treated with rosiglitazone: the Avantage study. Ann Endocrinol 2008 69 : 36 46.
30. Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009 373 : 473 481.
31. Russell-Jones D, Vaag A, Schmidtz O et al. Liraglutide vs. insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met + SU). Diabetologia 2009 52 : 2046 2055.
32. Buse J, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009 374 : 39 47.